BLAINJECTIONINJECTABLE
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
TOFIDENCE (tocilizumab) by Biogen is interleukin 6 receptor antagonists [moa]. Approved for rheumatoid arthritis, systemic juvenile idiopathic arthritis, giant cell arteritis and 1 more indications. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOFIDENCE (tocilizumab) is a monoclonal antibody that blocks the interleukin-6 receptor, reducing inflammatory signaling in autoimmune diseases. It is indicated for rheumatoid arthritis, systemic juvenile idiopathic arthritis, giant cell arteritis, and Takayasu arteritis. The drug was approved in September 2023 and is currently in growth phase.
Growth
Early-stage growth phase product with moderate competitive pressure (30/100) suggests expanding commercial team and opportunities in field sales, market access, and brand management roles.
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Worked on TOFIDENCE at Biogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.